Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07675174 · ClinicalTrials.gov registry record · Phase 1
Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT
A Phase 1 study, sponsored by Northwell Health.
- Not yet
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07675174: Clinical Trial Phase 1 study, sponsored by Northwell Health.
NCT07675174 is a Phase 1 study that has not yet begun recruiting, run by Northwell Health. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07675174, a Phase 1 study, has not yet begun recruiting, sponsored by Northwell Health.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling or 7/8 or 8/8 matched unrelated donor.
Primary Outcome
Phase I portion is determining the MTD of sitagliptin and bortezomib in combination with PTCy. Based on 3 planned dose levels, a maximum of 18 patients are included, although testing all three dose levels is not expected to be required.
Interventions
- DRUG Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2032-07-01 |
| Phase | Phase 1 |
What is known before NCT07675174 opens enrollment
NCT07675174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 1 intervention - of which Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD is the first listed.
NCT07675174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07675174 about?
NCT07675174 is a clinical study titled "Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT". Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling or 7/8 or 8/8 matched unrelated donor.
What is the current status of trial NCT07675174?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2026-07-01. Estimated completion is 2032-07-01.
What interventions are being tested in trial NCT07675174?
The interventions under investigation include: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD (DRUG).
Who is sponsoring clinical trial NCT07675174?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07675174's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI